# Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/VRTX
## Company Profile
- Ticker: VRTX
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: Boston, Massachusetts
- Tags: Biopharma, Pharmaceuticals, Diagnostics, Small Molecule Drugs
## Stock Data
- Close: 485.65 USD
- Market cap: 123194611357.62999 USD
- Last updated: 2026-07-17
## Business Overview
Vertex Pharmaceuticals is a commercial-stage biotech company best known for a durable launch franchise and a pipeline that still carries meaningful optionality. Investors pay close attention to how the company expands beyond its core commercial base.
## Why The Stock Is Moving

VRTX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in Boston, Massachusetts and listed on NASDAQ, Vertex is followed within the large-cap biotech universe for its mix of commercial scale and pipeline durability.

## Business Model

Vertex combines commercial execution with ongoing research investment. The market tends to focus on launch cadence, label expansion, and how efficiently the company uses its cash generation to build the next wave of assets.

## Landscape Position

Compared with earlier-stage peers, Vertex sits on the more mature side of the biotech landscape, where launch quality and pipeline breadth matter alongside catalyst timing.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.